Skip to main content
. 2018 Apr 9;27(12):2113–2124. doi: 10.1093/hmg/ddy118

Figure 7.

Figure 7.

 Inhibition of ODC with DFMO in Tsc2+/− mice decreases astrogliosis in the hippocampal CA1 region in a dose-dependent manner. (A) Time course of DFMO treatment of Tsc2+/− mice. Mice were treated with DFMO (250 or 500 mg/kg) by daily i.p. injection from P10 to P21 (denoted by hatched bar) and sacrificed for GFAP immunofluorescence (IF) at P21. (B) Quantification of hippocampal GFAP IF intensity from control mice and untreated and DFMO-treated Tsc2+/− mice. (C) Representative IF of control, (D) untreated Tsc2+/−, (E) 250 mg/kg DFMO-treated Tsc2+/− and (F) 500 mg/kg DFMO-treated Tsc2+/- hippocampi using anti-GFAP antibody to detect astrogliosis (scale bar = 100 µm). Astrocytes in the CA1 region (inset, scale bar = 20 µm). *P < 0.05.